318 related articles for article (PubMed ID: 18668134)
1. HOX expression patterns identify a common signature for favorable AML.
Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
[TBL] [Abstract][Full Text] [Related]
2. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
3. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
4. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
5. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.
Kawagoe H; Humphries RK; Blair A; Sutherland HJ; Hogge DE
Leukemia; 1999 May; 13(5):687-98. PubMed ID: 10374871
[TBL] [Abstract][Full Text] [Related]
6. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
Rozovskaia T; Feinstein E; Mor O; Foa R; Blechman J; Nakamura T; Croce CM; Cimino G; Canaani E
Oncogene; 2001 Feb; 20(7):874-8. PubMed ID: 11314021
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.
Novak RL; Harper DP; Caudell D; Slape C; Beachy SH; Aplan PD
Exp Hematol; 2012 Dec; 40(12):1016-27. PubMed ID: 22885519
[TBL] [Abstract][Full Text] [Related]
9. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
11. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
12. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.
Ferrando AA; Armstrong SA; Neuberg DS; Sallan SE; Silverman LB; Korsmeyer SJ; Look AT
Blood; 2003 Jul; 102(1):262-8. PubMed ID: 12637319
[TBL] [Abstract][Full Text] [Related]
14. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
15. 11q23/MLL rearrangements in adult acute leukemia.
Zotova OV; Lukianova AS; Valchuk MO; Karol YS; Shalay OO; Novak VL; Loginsky VE
Exp Oncol; 2021 Sep; 43(3):229-233. PubMed ID: 34591430
[TBL] [Abstract][Full Text] [Related]
16. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
[TBL] [Abstract][Full Text] [Related]
17. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
18. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
[TBL] [Abstract][Full Text] [Related]
19. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
[TBL] [Abstract][Full Text] [Related]
20. Expression of HOX genes in acute leukemia cell lines with and without MLL translocations.
Quentmeier H; Dirks WG; Macleod RA; Reinhardt J; Zaborski M; Drexler HG
Leuk Lymphoma; 2004 Mar; 45(3):567-74. PubMed ID: 15160920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
